DevGen

Last updated
Devgen NV
Company typeAcquired by Syngenta in 2013
Industry Agriculture and biotech
Founded Gent, Belgium (1997)
Headquarters
Belgium  OOjs UI icon edit-ltr-progressive.svg
Key people
 Thierry Bogaert, Founder, CEO
Remi Vermeiren, Chairman
Wim Goemaere, CFO
Products Pesticides, crop seeds, agricultural biotechnology
Website http://www.syngenta.com

Devgen is a Belgium-based multinational agricultural biotechnology company. It uses biotechnology and molecular breeding technologies to develop varieties of food crops. Its technology is marketed by outlicensing or selling seeds in India and South-East Asia. Devgen also develops nematicides.

Contents

History

RNA interference spin off

Devgen was founded as a spin-off of Ghent University and The Flemish Institute for Biotechnology in 1997 to commercialize intellectual property it licensed on the use of RNAi in nematodes and its use for screening for therapeutics and/or their targets. Its work focused on the nematode C. elegans as a model system, which functions as a model for human diseases, but also as a model for the kind of nematodes that are agricultural pests. [1] [2]

The company raised 37 million Euro in its first three years, first from the GIMV and Abingworth investment companies at its launch, then from the IWT, then from another round of private investors including ING, KBC, Life Science Partners, Sofindex, Rendex and Mercator, then from Polytechnos and Capricorn. [2] : 36–37  The received several subsequent grants from IWT. [3] [4] [5] [6] [7]

Devgen also struck R&D collaborations over its first six years, first with Janssen Pharmaceutica in 1998 in the field of target discovery for drugs and later with Merck and Genentech in the same field, and in 1998 it collaborated with FMC Corporation for the discovery of novel insecticides, and then with other ag companies like Sumitomo, Syngenta, Pioneer Hi-Bred. Devgen brought in 23 million Euro in funding from these partnerships through 2003. [2]

In 2004 it opened a second office in Singapore and moved into a new research building on the Ardoyen Technology Campus. [8]

Seed company

In June 2005, employing close to 100 people, Devgen raised more than 33 million euro in a successful IPO on Euronext Brussels. [9] Also in 2005, it established rice breeding stations in Kenya; it completed its first field trials there in 2006. [10] In 2005 it also launched field trials of its nematicide in Europe. [11]

In early 2007, Devgen and Monsanto announced a five-year collaboration in which the two companies would share technologies, with Devgen focusing the shared technology on the development of rice and other small cereal grains, and Monsanto using them to develop new traits for corn, cotton, and soybeans. [12] Later in 2007, Devgen acquired Monsanto's subsidiaries in India, Pakistan, and the Philippines that developed and sold hybrid seeds for 4 crops: rice, sunflower, sorghum and pearl millet, for about $26M. [13] Shortly thereafter, it announced its intention to spin off its pharma division. [14] In late 2008 it fired its 19 pharma employees, leaving about 200 remaining in its ag businesses. [14] In 2010, some former Devgen pharma employees started a pharmaceutical company, Amakem NV, to develop kinase inhibitors they had discovered at Devgen. [15] [16]

In 2009, Devgen and Monsanto broadened their collaboration, with Monsanto paying Devgen €20 million cash for broader rights to use Devgen's technology. [17]

Devgen's nematicide Iprodione, was approved in the Turkish market under the brandname Devguard for use on tomatoes and cucumbers in 2009, [18] was approved in Europe in 2010, [19] and was approved in the US as Enclosure for use in commercial peanut production in May 2010. [20] Devgen has a method-of-use patents for the use of iprodine to kill nematodes. [21]

Takeover by Syngenta

In September 2012, Syngenta placed a bid of 403 million euros ($522 million) for the acquisition of Devgen as part of a wave of large ag companies buying biotech companies. [22] [23] The offer came six months after the companies had signed an agreement under which Syngenta would have developed sprayable RNAi-based crop protection products based on Devgen's technology. [24] The rationale for Syngenta to acquire Devgen was stated by Syngenta spokeswoman Jennifer Gough as follows: "It's a very important expansion of our rice strategy, one of our eight key crops", she said. "We are also buying their competence in RNAi technology which will be relevant for us across a broad range of crops." [25] Devgen's shares were delisted from the NYSE in February 2013, [26] and the acquisition was completed in December 2013. [27]

Related Research Articles

The Monsanto Company was an American agrochemical and agricultural biotechnology corporation founded in 1901 and headquartered in Creve Coeur, Missouri. Monsanto's best-known product is Roundup, a glyphosate-based herbicide, developed in the 1970s. Later, the company became a major producer of genetically engineered crops. In 2018, the company ranked 199th on the Fortune 500 of the largest United States corporations by revenue.

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Mary-Dell Chilton</span> American biologist

Mary-Dell Chilton is one of the founders of modern plant biotechnology.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Pharming, a portmanteau of "farming" and "pharmaceutical", refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming or biopharming.

A biopesticide is a biological substance or organism that damages, kills, or repels organisms seen as pests. Biological pest management intervention involves predatory, parasitic, or chemical relationships.

<span class="mw-page-title-main">Genetically modified crops</span> Plants used in agriculture

Genetically modified crops are plants used in agriculture, the DNA of which has been modified using genetic engineering methods. Plant genomes can be engineered by physical methods or by use of Agrobacterium for the delivery of sequences hosted in T-DNA binary vectors. In most cases, the aim is to introduce a new trait to the plant which does not occur naturally in the species. Examples in food crops include resistance to certain pests, diseases, environmental conditions, reduction of spoilage, resistance to chemical treatments, or improving the nutrient profile of the crop. Examples in non-food crops include production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.

<span class="mw-page-title-main">Syngenta</span> Global provider of agricultural science and technology

Syngenta AG is a provider of agricultural science and technology, in particular seeds and pesticides with its management headquarters in Basel, Switzerland. It is owned by ChemChina, a Chinese state-owned enterprise.

<span class="mw-page-title-main">Pioneer Hi Bred International</span> American producer of hybrid seeds for agriculture

Pioneer Hi-Bred International, Inc. is a U.S.-based producer of seeds for agriculture. They are a major producer of genetically modified crops with insect and herbicide resistance.

<span class="mw-page-title-main">Iprodione</span> Chemical compound

Iprodione is a hydantoin fungicide and nematicide.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 km from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Thierry Bogaert is a Belgian scientist and businessman. He founded the Belgian biotech company Devgen in 1997 and was its managing director and CEO from 1997 onwards, until he sold the Devgen to Syngenta in 2012 for 400m EUR. During this time he led the science and business strategy of the company and took Devgen public on Euronext in 2005. Building on genetics as its core scientific strength, He developed Devgen into a leading provider of new crop protection technologies to the Agro industry and an Asian seed company that fundamentally redesigned Hybrid Rice delivering a pipeline of high yielding products for Indian and South East Asian markets. Prior to its sale to Syngenta, Devgen seeds were produced on >8000 ha and sold in ~20,000 retail shops across India, Indonesia and Philippines.

<span class="mw-page-title-main">Bayer</span> German multinational pharmaceutical and biotechnology company

The Bayer AG is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include: pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index.

BASF Plant Science is a subsidiary of BASF in which all plant biotechnology activities are consolidated. The company was founded in 1998 and employs approximately 700 people at 6 different locations worldwide. The headquarters of BASF Plant Science is located in Research Triangle Park and has research sites in the US, Canada, and Europe. The company mainly develops genetically modified seeds at these locations.

Ceres, Inc. was a biotechnology company based in Thousand Oaks, California, United States that operated from 1996 to 2016, when it was acquired by Land O'Lakes. The company was a spinoff from UCLA researchers. Its ultimate commercial products were seeds of genetically modified crops used for biofuel production. In addition to its operations in the United States, Ceres had a subsidiary in Brazil called Ceres Sementes do Brasil.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Arbutus Biopharma</span> Canadian Bio Tech Company

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

This is a timeline of Monsanto, a publicly traded American multinational agrochemical and agricultural biotechnology corporation headquartered in Creve Coeur, Greater St. Louis, Missouri.

References

  1. ↑ "Devgen page at VIB". Archived from the original on 2020-02-21. Retrieved 2014-12-31.
  2. 1 2 3 Johan Albrecht, Vlerick Leuven Gent Management School, Universiteit Gent Juni 2004 Biotech Cluster Project Biopharmaceutical Network Dynamics in Flanders and Sector Competitiveness Archived 2015-01-08 at the Wayback Machine
  3. ↑ Devgen Press release, January 9, 2003. Press release: Devgen Receives Grant For Ion Channel Research
  4. ↑ in-Pharma Technologist. 21 Nov, 2003 Grant helps Devgen explore drug mechanisms
  5. ↑ Devgen Press Release. November 25, 2004 Press release: Devgen Receives IWT Grant to Develop Novel Nematicides
  6. ↑ gate2biotech 7 Feb 2006 Devgen receives IWT grant to support crop protection R and D
  7. ↑ Devgen Press release. 26 Feb 2007 Devgen NV Receives IWT Grant to Support its Obesity Drug Discovery Program
  8. ↑ Cisco. Innovative biotechnology company opts for IP communications
  9. ↑ "Press release: Devgen Raises € 30 Million in Successful IPO" (PDF). Archived from the original (PDF) on 2006-10-16. Retrieved 2014-12-31.
  10. ↑ Devgen. February 7, 2007 Press release: Devgen moves ahead in its rice business plan, appoints management and senior advisor for its rice unit
  11. ↑ Devgen Press Release. March 07, 2007 Positive outcome of 2006 season of nematicide field trials
  12. ↑ Farm Futures. Feb 7, 2007 Devgen and Monsanto to Exchange Technology
  13. ↑ Monsanto Press Release. September 14, 2007 Press release: Devgen to Acquire Rice, Sunflower, Sorghum and Pearl Millet Businesses in India and Other Asian Countries From Monsanto Archived 2017-02-25 at the Wayback Machine
  14. 1 2 First Word Pharma. November 5th, 2008 Devgen announces the intention to close its pharma division and to fully focus on the development of its agro business
  15. ↑ Amakem Press Release. February 11, 2010 Amakem, a new Flemish drug discovery company starts operations for treatments of major chronic diseases Archived 2015-01-01 at the Wayback Machine
  16. ↑ BioPharmaceutiques 2009 Successful start-up for Amakem Archived 2016-03-04 at the Wayback Machine
  17. ↑ Genetic Engineering and Biotechnology News. Apr 24, 2009. Monsanto Buys Broader Rights to Devgen Technologies for $26.5M
  18. ↑ AgroNews Nov. 2, 2009 Devgens nematicide Devguard receive regulatory approval in Turkey
  19. ↑ AgroNews. Sep. 3, 2010 EU approved iprodione’s use extension
  20. ↑ AgroNews. May. 24, 2010 Devgen launches Enclosure nematicide in U.S.
  21. ↑ Reuters. May 8, 2009 2010 launch of Devgen's nematicide "Enclosure(R)" in the United States
  22. ↑ Patrick Winters for Bloomberg News. Sep 21, 2012 Syngenta to Buy Biotech Seedmaker Devgen for $523 Million
  23. ↑ Doug Macron for GenomeWeb. Sep 27, 2012 Syngenta Makes $518M Offer to Buy Devgen, Boost Access to RNAi Tech for Ag-Bio
  24. ↑ Marie Daghlian for The Burrill Report. Sept 20, 2012. Syngenta Pushes into Biologic Pest Control
  25. ↑ Reuters Sep 21, 2012 Syngenta pays hefty premium to snap up Devgen
  26. ↑ Syngenta press release. February 27, 2013 Delisting of Devgen NV Archived 2016-03-04 at the Wayback Machine
  27. ↑ The Hindu. December 15, 2013. Syngenta completes acquisition of Devgen


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.